Finance

Lists
SION:NASDAQ
Sionna Therapeutics Inc
$6.46
-1.22%
(-0.080) 1D
$6.18
-4.33% (-0.28)
Pre-market
Closed: Aug 14, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SION...
Open
$6.24
High
$6.66
Low
$6.15
Mkt. cap
292.07M
Avg. vol.
2.80M
Volume
12.95K
52-wk high
$54.97
52-wk low
$4.01
EPS
-$2.17
Shares outstanding
45.21M
No. of employees
59
Open
$6.24
High
$6.66
Low
$6.15
Mkt. cap
292.07M
Avg. vol.
2.80M
Volume
12.95K
52-wk high
$54.97
52-wk low
$4.01
EPS
-$2.17
Shares outstanding
45.21M
No. of employees
59
News stories
From web sources and news partners
About Sionna Therapeutics Inc
CEO-
Employees59
Founded2019
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitesionnatx.com
Analyst ratings
Based on 11 analysts giving stock ratings to SION in the past 3 months
Hold
Buy
1
Hold
10
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for SION in the last 3 months.
Highest
Current $6.46
$63.00 (+875.23%)
Average
$15.17 (+134.83%)
Lowest
$5.00 (-22.60%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ilya Zubkov
Freedom Capital Markets
Hold
Maintained
$5.00
-22.6%
08/11/2026
Gaurav Maini
LifeSci Capital
Hold
Downgraded
$6.00
-7.1%
08/10/2026
Kambiz Yazdi
BTIG
Hold
Downgraded
-
-
08/10/2026
Yatin Suneja
Guggenheim
Hold
Downgraded
-
-
08/10/2026
Jonathan Wolleben
Citizens JMP
Hold
Downgraded
-
-
08/10/2026
Christopher Raymond
Raymond James
Hold
Downgraded
-
-
08/10/2026
Brian Abrahams
RBC Capital
Hold
Upgraded
$5.00
-22.6%
08/10/2026
Laura Chico
Wedbush
Hold
Downgraded
$5.00
-22.6%
08/10/2026
Paul Matteis
Stifel Nicolaus
Hold
Downgraded
$7.00
+8.4%
08/10/2026
Debanjana Chatterjee
JonesTrading
Hold
Downgraded
$63.00
+875.2%
08/10/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
07/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
16.04M
15.17M
18.96M
21.86M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.76M
8.44M
10.64M
10.61M
Operating expense
23.80M
23.61M
29.60M
32.47M
Total operating expenses
23.80M
23.61M
29.60M
32.47M
Operating income
-23.80M
-23.61M
-29.60M
-32.47M
Other non operating income
71.00K
-
-
-3.00K
EBT including unusual items
-20.28M
-20.44M
-26.78M
-29.89M
EBT excluding unusual items
-20.28M
-20.44M
-26.78M
-29.89M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20.28M
-20.44M
-26.78M
-29.89M
Net profit margin
-
-
-
-
Earnings per share
-0.46
-0.46
-0.60
-0.66
Interest and investment income
3.46M
3.17M
2.82M
2.59M
Interest expense
-
-
-
-
Net interest expenses
3.46M
3.17M
2.82M
2.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
-23.62M
-23.46M
-29.44M
-32.32M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps